Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin

Acta Trop. 2011 Sep:120 Suppl 1:S91-9. doi: 10.1016/j.actatropica.2010.05.004. Epub 2010 May 24.

Abstract

Reduction in Onchocerca volvulus skin microfilarial densities after treatment with ivermectin shows wide between-host variation. Data from two separate studies conducted in Cameroon on onchocerciasis patients treated for the first time with ivermectin were analyzed to identify host factors associated with microfilarial density at different time-points after treatment. In one site (Nkam valley), the dataset included 103 adult males for whom age, number of palpable onchocercal nodules and microfilarial densities on D0 (pre-treatment), D15, D80 and D180 were available. In the other site (Vina valley), analyses were conducted on 965 individuals of both sexes aged 5 years and over; in this dataset, available information included age, gender, exact dose of ivermectin received, onchocerciasis endemicity level in the village of residence and microfilarial densities on D0 and D180. Negative binomial regression models of microfilarial density at the different intervals post-treatment were fitted, using maximum likelihood, with the available independent variables. Gender and age were found to be associated with microfilarial density on D180. The initial microfilarial density influenced post-treatment densities at all the time-points. All other things being equal, microfilarial densities on D180 were higher in individuals harbouring a higher number of nodules or living in communities with high endemicity levels. This study demonstrates that O. volvulus microfilarial density measured after a first treatment with ivermectin, and thus probably the rate of skin repopulation by microfilariae (mf) varies according to several host factors. Should such factors also influence ivermectin efficacy after repeated treatment, then they should be taken into account to determine whether sub-optimal responses to treatment reported from various areas in Africa are actually due to parasite-related factors, particularly to the emergence of resistant populations.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase IV
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Animals
  • Child
  • Child, Preschool
  • Drug Resistance
  • Female
  • Filaricides / administration & dosage
  • Filaricides / therapeutic use*
  • Host-Pathogen Interactions
  • Humans
  • Ivermectin / administration & dosage
  • Ivermectin / therapeutic use*
  • Male
  • Microfilariae / drug effects*
  • Microfilariae / growth & development
  • Onchocerca volvulus / drug effects*
  • Onchocerca volvulus / growth & development
  • Onchocerciasis / drug therapy*
  • Onchocerciasis / parasitology
  • Onchocerciasis / pathology
  • Sex Factors
  • Skin / parasitology*
  • Skin / pathology
  • Treatment Outcome
  • Young Adult

Substances

  • Filaricides
  • Ivermectin